Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer.
about
Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast CancerCost-utility analyses of drug therapies in breast cancer: a systematic review.Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer.Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.
P2860
Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Cost-effectiveness analysis of ...... tment for early breast cancer.
@ast
Cost-effectiveness analysis of ...... tment for early breast cancer.
@en
type
label
Cost-effectiveness analysis of ...... tment for early breast cancer.
@ast
Cost-effectiveness analysis of ...... tment for early breast cancer.
@en
prefLabel
Cost-effectiveness analysis of ...... tment for early breast cancer.
@ast
Cost-effectiveness analysis of ...... tment for early breast cancer.
@en
P2093
P2860
P356
P1476
Cost-effectiveness analysis of ...... atment for early breast cancer
@en
P2093
Ali Aboutorabi
Hossein Ghaderi
Maryam Ghiasipour
Masoud Salehi
P2860
P304
P356
10.5539/GJHS.V7N1P98
P577
2014-08-14T00:00:00Z